12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OMS824: Additional Phase I data

A double-blind, placebo-controlled Phase I trial in 24 healthy volunteers showed that multiple ascending-doses of OMS824 for 7-10 days were well tolerated and displayed a half-life consistent with once-daily dosing. The only apparent treatment-related...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >